Transplant Status — Clinical Documentation Guide (2026)

🔍 Definition

Transplant status is a clinical condition category in ICD-10-CM that captures the long-term state of a patient who has received a solid organ, tissue, or hematopoietic cell transplant. Per the FY2026 ICD-10-CM Official Guidelines (CMS), codes from subcategory Z94 (transplanted organ and tissue status) are used to indicate the presence of a functioning graft when no complication is documented. These are status codes — they reflect a patient’s historical and ongoing physiological condition rather than an active disease process.

A patient with transplant status may present at any encounter for any reason; the transplant status code is reportable whenever it affects care or management. The distinction between a functioning transplant (Z94.x), a failed or rejected transplant (T86.xx), and post-transplant aftercare (Z48.2x) is critical for accurate coding, risk adjustment, and reimbursement. Chronic immunosuppression, graft-versus-host risk, and organ-specific complications make transplant status one of the most clinically significant status code families in ICD-10-CM.

🗂️ Alternative Terminology

Transplant status is documented under many names across specialties. Coders and CDI specialists must recognize all variations to ensure correct code selection.

🩺 Signs & Symptoms

Transplant recipients may present with symptoms related to the transplanted organ’s function, rejection, infection, immunosuppressive therapy side effects, or unrelated conditions. Key clinical signs and symptoms by category include:

General / Systemic: Fatigue, malaise, unexplained fever (early rejection or infection signal), weight changes, hypertension (common with calcineurin inhibitors), hyperlipidemia, post-transplant diabetes mellitus (PTDM/NODAT).

Renal Transplant (Z94.0 / T86.1x): Rising serum creatinine, decreased urine output, new or worsening proteinuria, hematuria, graft tenderness (acute rejection), hypertension, BK virus nephropathy (BKV), recurrent glomerulonephritis in the allograft.

Heart Transplant (Z94.1 / T86.2x): Dyspnea, exercise intolerance, edema, reduced ejection fraction on echocardiogram, cardiac allograft vasculopathy (CAV), palpitations, syncope; endomyocardial biopsy is the gold standard for rejection surveillance.

Liver Transplant (Z94.4 / T86.4x): Elevated liver enzymes (AST/ALT, GGT, alkaline phosphatase), jaundice, ascites, coagulopathy, bile duct complications (stricture, leak), hepatic artery thrombosis.

Lung Transplant (Z94.2 / T86.81x–T86.83): Declining FEV1, dyspnea, cough, bronchiolitis obliterans syndrome (BOS) — hallmark of chronic rejection, recurrent respiratory infections, pleural effusion.

Bone Marrow / Stem Cell (Z94.81, Z94.84 / T86.0, T86.5): Pancytopenia, graft failure, graft-versus-host disease (GVHD) — acute (maculopapular rash, nausea, diarrhea, jaundice) vs. chronic (scleroderma-like changes, sicca symptoms, obliterative bronchiolitis), secondary malignancy, post-transplant lymphoproliferative disorder (PTLD).

Immunosuppression-Related: Opportunistic infections (CMV, Pneumocystis jirovecii pneumonia, aspergillosis, cryptococcosis), malignancy risk (skin cancers, PTLD), nephrotoxicity (calcineurin inhibitors), neurotoxicity, tremors, electrolyte imbalances.

🧭 Differential Diagnosis

Distinguishing transplant status (functioning graft) from complications and other conditions is essential for correct code assignment. The table below outlines key diagnostic differentials.

📋 Clinical Indicators for Coders/CDI

Use the following indicators to identify transplant status coding opportunities in the health record. These triggers help CDI specialists ensure complete and accurate capture at every encounter.

🦴 Anatomy & Pathophysiology

Solid Organ Transplantation: Organ transplantation replaces a failed or failing native organ with an allograft from a deceased or living donor. The transplanted organ is surgically anastomosed to the recipient’s vasculature and, for kidney transplants, to the urinary system. The allograft is recognized as foreign by the recipient’s immune system, making lifelong immunosuppression necessary to prevent rejection.

Rejection Mechanisms: Rejection is classified by timing and mechanism per UpToDate clinical references:

• Hyperacute rejection: Occurs within minutes to hours; mediated by preformed antibodies; rare with modern crossmatch testing.
• Acute cellular rejection (ACR): T-cell–mediated; typically within weeks to months; treated with high-dose corticosteroids and, if severe, antithymocyte globulin (ATG).
• Antibody-mediated rejection (AMR): Donor-specific antibodies (DSA) attack vascular endothelium; treated with plasmapheresis, IVIG, rituximab.
• Chronic rejection / chronic allograft dysfunction: Progressive fibrosis and vascular changes over years; manifests as bronchiolitis obliterans syndrome (BOS) in lungs, cardiac allograft vasculopathy (CAV) in hearts, and chronic allograft nephropathy in kidneys; less amenable to treatment.

Hematopoietic Cell Transplantation (HCT): Bone marrow (BMT) and peripheral blood stem cell transplants (Z94.81, Z94.84) replace the recipient’s hematopoietic system. Allogeneic transplants carry risk of graft-versus-host disease (GVHD) in addition to graft failure. The graft-versus-leukemia (GVL) effect is therapeutically beneficial. Autologous transplants (using the patient’s own cells) carry no GVHD risk but higher relapse risk.

Immunosuppression Pharmacology: Standard immunosuppression typically involves a calcineurin inhibitor (tacrolimus or cyclosporine), a purine synthesis inhibitor (mycophenolate mofetil or azathioprine), and corticosteroids. Maintenance regimens are lifelong for solid organs. mTOR inhibitors (sirolimus, everolimus) may substitute or supplement calcineurin inhibitors. Complications of immunosuppression include nephrotoxicity, neurotoxicity, hypertension, hyperlipidemia, bone loss, PTDM, and increased infection and malignancy risk.

Post-Transplant Lymphoproliferative Disorder (PTLD): PTLD (D47.Z1) is a spectrum of lymphoid proliferations driven by Epstein-Barr virus (EBV) reactivation in the setting of immunosuppression. It ranges from benign polyclonal hyperplasia to aggressive monomorphic PTLD resembling diffuse large B-cell lymphoma. Incidence is highest in the first year post-transplant. Treatment includes reduction of immunosuppression, rituximab, and chemotherapy for aggressive forms.

💊 Medication Impact / Treatment

Transplant recipients require lifelong medication management. The following drug classes and specific agents are central to transplant care and have significant coding implications.

Calcineurin Inhibitors: Tacrolimus (Prograf, Astagraf) and cyclosporine (Sandimmune, Gengraf) are the backbone of solid organ immunosuppression. Nephrotoxicity is a major concern — rising creatinine may represent calcineurin inhibitor toxicity rather than rejection; this distinction must be documented. HCPCS codes J7502 (cyclosporine oral) and J7507/J7508 (tacrolimus) apply to facility-administered doses.

Antiproliferative Agents: Mycophenolate mofetil (CellCept, J7517) and mycophenolic acid (Myfortic, J7518) inhibit purine synthesis. Azathioprine is an older alternative. These agents reduce rejection risk but increase infection susceptibility.

mTOR Inhibitors: Sirolimus (Rapamune, J7520) and everolimus (Zortress, J7527) inhibit the mammalian target of rapamycin pathway. Used in calcineurin inhibitor–sparing regimens or as primary immunosuppression in select patients.

Corticosteroids: Prednisone and methylprednisolone are used for maintenance (Z79.52 systemic steroids) and rejection treatment (pulse dosing). Long-term use contributes to PTDM, osteoporosis, adrenal suppression, and Cushingoid features. Coding: Z79.52 (long-term systemic steroids) should be assigned when chronic steroid use affects management.

Anticoagulants and Antiplatelet Agents: Some transplant patients require anticoagulation (Z79.01 long-term anticoagulant use). Distinguish Z79.01 (anticoagulants) from Z79.02 (antithrombotics/antiplatelet) for accurate coding.

Immunomodulators: Z79.624 (long-term use of immunomodulators) applies to immunosuppressive drugs used to maintain graft function. This Z code should be assigned at every encounter where immunosuppressants are documented as current medications.

Prophylactic Antimicrobials: Post-transplant patients typically receive prophylaxis against CMV (valganciclovir), Pneumocystis (trimethoprim-sulfamethoxazole), fungal infections (fluconazole, voriconazole), and toxoplasmosis. These represent additional code opportunities (Z79.2 long-term antibiotic use; individual drug codes).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following guidelines govern transplant status coding per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting.

Section I.C.19 — Complications of Transplanted Organs and Tissue

Per ICD-10-CM Official Guidelines Section I.C.19.g, a transplant complication code from category T86 is assigned only when the condition documented meets both of the following criteria: (1) it is a complication of the transplant, and (2) it adversely affects the transplanted organ. Not all conditions affecting a transplant recipient are transplant complications — a patient with a kidney transplant who develops hypertension due to the native arterial system should not have T86 assigned unless the hypertension is documented as a complication of the transplant itself.

Chronic vs. Acute Rejection: ICD-10-CM does not provide separate code axis positions for acute vs. chronic rejection within T86; however, documenting “acute rejection” vs. “chronic rejection” is critical because:

• Acute rejection typically triggers T86.x1 (rejection).
• Chronic rejection (chronic allograft dysfunction) also maps to rejection codes but carries different clinical management implications. Coders should query for explicit documentation of “acute” or “chronic” when the distinction is not stated.
• Separate encounters for acute vs. chronic rejection may have different DRG assignment weight implications.

Kidney Transplant and CKD

Per ICD-10-CM Official Guidelines Section I.C.14: Patients who have undergone kidney transplant may still have some degree of CKD because the kidney transplant may not fully restore normal kidney function. The presence of CKD alone does not constitute a transplant complication. Assign the appropriate CKD code (N18.1–N18.6) in addition to Z94.0 when CKD is documented. However, do not assume a CKD stage from creatinine values alone — the provider must explicitly document the CKD stage for it to be coded. If the transplant is functioning and the provider does not document a CKD stage, assign only Z94.0.

ESRD and Transplant Status

Per the FY2026 ICD-10-CM Guidelines, when a patient with prior ESRD receives a functioning kidney transplant, ESRD (N18.6) and dialysis status (Z99.2) should no longer be assigned unless: (1) the graft has failed and the patient has returned to dialysis, or (2) the provider documents ongoing ESRD alongside the transplant. Z94.0 replaces the ESRD coding construct for functioning grafts.

Transplant Status as Secondary Code

Z94.x codes are never principal diagnoses in inpatient settings unless the encounter is specifically for evaluation of the transplanted organ status with no other condition driving the admission. At outpatient encounters, Z94.x may be sequenced as first-listed when the encounter is specifically for transplant follow-up (post-transplant monitoring). In most encounters, Z94.x is a secondary/additional code providing context for the patient’s immunosuppressed state.

Post-Transplant Aftercare (Z48.2x)

Category Z48.2x applies to encounters specifically for aftercare following organ transplant, when no complication is encountered. Per ICD-10-CM guidelines, Z48.2x includes the type of organ. If a complication is identified during the aftercare visit, code the complication (T86.xx) instead of Z48.2x; both may be coded if appropriate.

Annual Capture Importance

Z94.x status codes should be reported at every encounter where the transplant status affects the patient’s care, assessment, or treatment decisions. Dropping these codes in subsequent years results in RAF score gaps and undercoding of chronic conditions. CDI and coding teams should verify Z94.x presence at minimum annually across all encounter types.

🔢 ICD-10-CM Code Set (FY2026)

All codes verified against the FY2026 ICD-10-CM Tabular List (CMS).

Z94 — Transplanted Organ and Tissue Status

Z48.2x — Aftercare Following Transplant

T86.xx — Complications of Transplanted Organs and Tissue

Additional Relevant Codes

🔎 Indexing

Use the FY2026 ICD-10-CM Alphabetic Index pathways below for accurate code location.

🏥 CPT (2026)

The following CPT codes are relevant to post-transplant monitoring, biopsy procedures, and hematopoietic cell transplantation per the AMA CPT 2026 codebook.

🧾 HCPCS (2026)

Immunosuppressive drugs administered in the facility or billed under Part B use the following CMS HCPCS Level II codes. These apply to Medicare-covered immunosuppressive drug claims and are essential for facility billing and Part B drug reporting.

📚 AHA Coding Clinic (Recent Guidance)

The following guidance from the AHA Coding Clinic for ICD-10-CM/PCS applies to transplant status coding:

• Kidney Transplant with CKD: Per AHA Coding Clinic, First Quarter 2022, a patient with kidney transplant who has CKD documented by the provider should be assigned both Z94.0 and the appropriate CKD stage code. The presence of CKD after transplant does not constitute a transplant complication unless the provider specifically links the CKD to a transplant complication (rejection, etc.).
• PTLD Coding: AHA Coding Clinic has affirmed that D47.Z1 is the correct code for post-transplant lymphoproliferative disorder, regardless of histologic subtype, unless the PTLD has evolved into a clearly defined lymphoma category with its own specific code. Assign Z94.x for the underlying transplant.
• Chronic vs. Acute Rejection: Guidance supports querying providers when documentation does not specify acute vs. chronic rejection, as this distinction affects severity of illness and risk of mortality classifications in DRG assignment.
• GVHD: GVHD codes (D89.81x) are not transplant complications per se under T86 — they are coded from the hematopoietic and immune category. Assign D89.81x in addition to Z94.81 or Z94.84 as applicable.
• Cardiac Allograft Vasculopathy (CAV): Per AHA Coding Clinic guidance, CAV should be coded as T86.290 (cardiac allograft vasculopathy) per the FY2026 tabular inclusion terms — it is a form of chronic rejection of the coronary vasculature.

💰 HCC / Risk Adjustment (v28)

Transplant status codes carry significant risk adjustment implications under the CMS-HCC Model Version 28, used for Medicare Advantage risk adjustment beginning 2024 and phased in for FY2026.

✍️ CDI Query Templates

All queries below follow ACDIS and AHIMA compliant, non-leading, multiple-choice format.

🧑‍⚕️ Treatments (Clinical)

Rejection Treatment — Acute Cellular: High-dose intravenous methylprednisolone (pulse steroids) is first-line for biopsy-proven acute cellular rejection in solid organ transplants. Steroid-resistant rejection may require antithymocyte globulin (ATG/Thymoglobulin), plasmapheresis, or IVIG per Kidney International transplant guidelines.

Rejection Treatment — Antibody-Mediated: AMR treatment includes plasmapheresis/therapeutic plasma exchange, IVIG, rituximab (anti-CD20), and eculizumab (anti-C5) in refractory cases. Emerging therapies include clazakizumab and imlifidase per investigational protocols.

Maintenance Immunosuppression Modification: Dose adjustments of calcineurin inhibitors (targeting trough levels), mTOR inhibitor substitution for CNI-sparing, and steroid withdrawal protocols are common management strategies during stable post-transplant periods.

PTLD Treatment: Reduction of immunosuppression (RIS) is first-line for PTLD — this carries rejection risk and requires close monitoring. Rituximab is used for CD20+ PTLD. R-CHOP chemotherapy for aggressive PTLD subtypes. Antiviral therapy (valganciclovir) for EBV-positive disease. Radiation for localized disease per NCCN Guidelines for B-cell Lymphomas.

GVHD Treatment: Systemic corticosteroids remain first-line for acute GVHD. Steroid-refractory acute GVHD may be treated with ruxolitinib (JAK inhibitor, FDA-approved), ibrutinib, or extracorporeal photopheresis. Chronic GVHD management per NIH GVHD Consensus Criteria includes ibrutinib, belumosudil, and ruxolitinib.

Kidney Transplant — BK Virus: No FDA-approved antiviral exists for BK virus. Management involves reduction of immunosuppression, with cidofovir or leflunomide as off-label options in severe BKVN. Serial monitoring of BK viremia guides therapy per KDIGO transplant guidelines (KDIGO Transplant Guideline 2024).

Opportunistic Infection Prophylaxis and Treatment: CMV disease (in high-risk CMV D+/R− pairs) treated with intravenous ganciclovir or oral valganciclovir. PJP (Pneumocystis) treated with high-dose trimethoprim-sulfamethoxazole. Invasive fungal infections managed with voriconazole (Aspergillus) or liposomal amphotericin B.

🎓 Patient Education / Summary

What does “transplant status” mean? Having a “transplant status” code in your medical record simply means your healthcare providers are documenting that you have received an organ or tissue transplant. This is important information that helps your entire care team understand your medical history, especially because you take medications to prevent rejection and are at increased risk for certain infections and conditions.

Why is it important to mention your transplant at every visit? Many medications and treatments interact with your anti-rejection drugs. By reminding every provider — including dentists, urgent care, and emergency providers — of your transplant, you help prevent dangerous drug interactions and ensure your care is coordinated properly. Your transplant team should always be informed of any new medications, infections, or procedures.

Signs that may indicate a problem with your transplant:

• Kidney transplant: Reduced urine output, swelling, tenderness over the transplant site, rising creatinine
• Heart transplant: Shortness of breath, new fatigue, swelling in legs, palpitations
• Liver transplant: Yellowing of skin or eyes (jaundice), dark urine, abdominal pain
• Lung transplant: Worsening shortness of breath, new cough, declining exercise tolerance
• Any transplant: Fever (may indicate infection or rejection), unexplained weight gain, confusion

Long-term follow-up: Post-transplant care requires lifelong follow-up with your transplant center. Regular lab monitoring, biopsies (as scheduled by your team), medication adjustments, and screening for post-transplant complications — including skin cancer, PTLD, post-transplant diabetes, and bone loss — are part of routine transplant care. Per transplant patient education guidelines, adherence to medications and follow-up appointments is the most important factor in long-term graft survival.

For coders and CDI specialists — annual capture reminder: Transplant status codes (Z94.x) should appear in every encounter where the transplant affects care. Do not allow these codes to “fall off” the problem list. Annual recapture ensures accurate RAF scoring, population health reporting, and care coordination flags for the patient’s entire care team.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)